Success Story: EB1A Approved Despite RFE! Our Firm Secured Success For an Indian Principal Scientist with Direct Premium Service

Client’s Testimonial:

“I had a wonderful experience working with Chen Immigration. My attorney was knowledgeable, patient, and very responsive. I think the lawyers did a great job with the petition letter, collecting all the relevant data and information to make a strong case. They know what they are doing, and their suggestions along the way were very helpful. I thank the team at Chen Immigration for handling my case and guiding me through the whole process with their prompt and detailed responses to my questions. I am waiting for the case to be approved and hope for a successful outcome!”

On September 18^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Principal Scientist in the Field of Pharmaceutical Sciences (Approval Notice).

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Principal Scientist

Country of Origin: India

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: September 18th, 2025

Processing Time: 3 months, 26 days (Premium Processing Requested)

Case Summary:

We are pleased to announce the approval of an I-140 EB1A petition for our client, an accomplished researcher in pharmaceutical sciences. With a Ph.D. and M.S. in pharmaceutical sciences, the Client has built a strong record of advancing targeted drug delivery systems and formulations with direct impact on cancer treatment and autoimmune diseases.

Transforming Pharmaceutical Sciences Through Drug Delivery Innovation

The Client’s work is particularly well-known for pioneering targeted liposomal delivery of resveratrol for the treatment of glioblastoma (GBM), one of the most challenging brain cancers. Their broader body of research addresses pressing issues in oncology and chronic disease management, including polymeric micelles to improve solubility and delivery of anticancer drugs, liposome-based immunotherapy for autoimmune conditions, and magnetic liposomes for cancer imaging and therapy. By designing innovative and practical drug delivery systems, the Client has significantly advanced therapeutic strategies that improve efficacy while minimizing side effects.

Scholarly Record and Research Impact

The petition highlighted the Client’s outstanding record of publication and scholarly influence, including:

14 peer-reviewed journal articles (6 first- or co-first-authored)
1 peer-reviewed conference article
8 abstracts (3 first-authored)
4 book chapters (3 first-authored)
1 first-authored patent and 1 Patent Cooperation Treaty (PCT) application

The Client’s publications have been cited 1,966 times, placing them among the top 1% most highly cited authors in pharmaceutical sciences over the past decade. Their research has not only contributed to advancing therapeutic delivery technologies but has also shaped subsequent studies worldwide. In addition, the Client has served as a peer reviewer at least 21 times, with invitations from some of the most selective and high-impact journals in the field.

Recognition and Support

The strength of the petition was reinforced by four letters of recommendation from leading experts in pharmaceutical sciences, who attested to the originality and global significance of the Client’s contributions.

“It is crucial that she is granted the opportunity to pursue her pioneering work without interruption, ensuring that the United States can fully capitalize on her invaluable contributions to the advancement of the medical sciences and healthcare innovation.”

The Client’s research has also attracted prestigious funding support, including from Hoffmann-La Roche, further underscoring the importance and applicability of their work to pressing healthcare challenges.

A Successful Outcome

USCIS agreed that the Client’s record demonstrated both sustained international recognition and original contributions of major significance, leading to the approval of their EB1A petition. This success underscores their critical role in advancing drug delivery and therapeutic development, with implications for improving cancer care, autoimmune disease treatment, and global health outcomes.

At NAILG, we are proud to have assisted the Client in preparing a strong, evidence-based petition. Their success highlights both their exceptional achievements and our firm’s expertise in navigating the EB1A process. We look forward to seeing their continued contributions to advancing pharmaceutical sciences in the United States.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.